Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
119 hedge funds and large institutions have $78.7M invested in Merrimack Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 116 → 119 (+3)
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
49% less call options, than puts
Call options by funds: $242K | Put options by funds: $473K
68% less capital invested
Capital invested by funds: $246M → $78.7M (-$167M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.12M |
| 2 |
Morgan Stanley
New York
|
+$806K |
| 3 |
JGC
J. Goldman & Co
New York
|
+$693K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$386K |
| 5 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.98M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.37M |
| 4 |
TA
Teachers Advisors
New York
|
-$3.84M |
| 5 |
BlackRock
New York
|
-$3.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
126
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$20K | -826 | Closed |
|
|
FPF
127
FNY Partners Fund
New York
| – | -$10K | -441 | Closed |
|
128
SEI Investments
Oaks,
Pennsylvania
| – | -$7K | -280 | Closed |
|
|
WA
129
WFG Advisors
Dallas,
Texas
| – | -$3K | -127 | Closed |
|
|
FANJ
130
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$2K | -64 | Closed |
|
MACK Hedge Fund Activity: Q2 2017 in Review
119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2017, worth a combined $78.7M — down 68% from $246M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MACK positions and 15 closed out — a net gain of 3 holders — while 31 added to existing stakes and 36 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.12M. The largest seller was State Street, cutting an estimated $11.3M.
- 119 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2017, up from 116 in Q1 2017.
- Funds reported $78.7M of Merrimack Pharmaceuticals, Inc. stock for Q2 2017, down 68% quarter-over-quarter.
- 18 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2017 and 15 closed out, a net change of +3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2017 was Millennium Management, an estimated $1.12M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2017 was State Street, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2017.